During a live virtual event, Sumanta K. Pal, MD, discussed with participants how their experience with immunotherapy and tyrosine kinase inhibitor therapies aligned with the data from pivotal clinical trials. This is the second of 2 articles based on this event.
At a live virtual event, Saketh Guntupalli, MD, discussed with participants the role of PARP inhibitors in the first-line setting for patients with advanced ovarian cancer.
During a Targeted Oncology case-based roundtable event, Saad Z. Usmani, MD, MBC, discussed the case of a patient who progressed on first- and second-line therapy for multiple myeloma and did not receive a stem cell transplant.
During a Targeted Oncology case-based roundtable event, Timothy M. Kuzel, MD, discussed the treatment options for patients with clear cell renal cell carcinoma.
During a case-based roundtable event, Javier L. Munoz, MD, MBA, discussed data supporting the use of newer therapies for patients with relapsed/refractory diffuse large B-cell lymphoma.
Richard S. Finn, MD, led a discussion on the management of patients with advanced hepatocellular carcinoma.
Anthony Mato, MD, discusses the case of a 76-year-old man with stage IV chronic lymphocytic leukemia.
Elisabet E. Manasanch, MD, MHSc led a discussion on treating relapsed/refractory multiple myeloma with BCMA targeted therapy.
During a Targeted Oncology case-based roundtable event, Erika P. Hamilton, MD, discussed the choice of first- and second-line therapy for a patient with triple-negative breast cancer following adjuvant chemotherapy.
During a Targeted Oncology case-based roundtable event, Andrew Kuykendall, MD, discussed the treatment options for a patient with myelofibrosis based on factors including platelet count.
During a live virtual event, Edwin M. Posadas, MD, discussed patient factors for choosing the type of therapy to use after progression on androgen receptor therapy and chemotherapy with participants.
During a Targeted Oncology case-based roundtable event, Chung-Han Lee, MD, PhD, discussed the latest data supporting the use of lenvatinib/pembrolizumab as frontline therapy for patients with advanced clear cell renal cell carcinoma.
During a Targeted Oncology case-based roundtable event, Wade T. Iams, MD, discussed the case of a patient who progressed following a partial response to platinum-based chemotherapy for extensive-stage small cell lung cancer.
During a Targeted Oncology case-based roundtable event, Cristina Gasparetto, MD, discussed data supporting the use of selinxor for patients with relapsed/refractory multiple myeloma.
During a live virtual event, Robert J. Motzer, MD, discussed the role of risk assessment in treating a patient with clear cell renal cell carcinoma. This is the first of 2 articles based on this event.
During a live virtual event, John O. Mascarenhas, MD, discussed the PERSIST-1 and PERSIST-2 trials of pacritinib for patients with myelofibrosis with lower platelet counts.
During a live virtual event, Zofia Piotrowska, MD, MHS, discussed the National Comprehensive Cancer Network guidelines for molecular testing for a patient with advanced non–small cell lung cancer, and how to approach a patient who is found to have an EGFR exon 20 insertion. This is the first of 2 articles based on this event.
During a Targeted Oncology case-based roundtable event, Sumanta K. Pal, MD, discussed the choice of frontline therapy for a favorable-risk patient with advanced clear cell renal cell carcinoma.
During a live virtual event, Benjamin P. Levy, MD, discussed the case of a patient with non–small cell lung cancer and an EGFR exon 19 deletion. This is the second of two articles based on this event.
During a live virtual event, Brea C. Lipe, MD, discussed what considerations affect the choice of triplet or quadruplet therapy for a patient with transplant-eligible multiple myeloma.
Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with previously untreated clear cell renal cell carcinoma. Vote in the polls on what you would have chosen if this was your patient.
During a Targeted Oncology case-based roundtable event, Ajay Kandra, MD, discussed with participants the challenges and treatment options for a patient with extensive-stage small cell lung cancer.
During a Targeted Oncology case-based roundtable event, Pallawi Torka, MD, discussed with participants when to consider a patient for chimeric antigen receptor T-cell therapy and what alternative treatments to use for a patient with relapsed/refractory diffuse large B-cell lymphoma.
During a Targeted Oncology case-based roundtable event, Daniel R. Couriel, MD, MS, MBA, discussed how to predict risk of acute graft-vs-host-disease and manage its effects on patients with hematologic malignancies.
During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discussed the case of a patient with hepatocellular carcinoma whose comorbidities impacted the choice of treatment.
During a Targeted Oncology case-based roundtable event, Alison K. Conlin, MD, discussed with participants their choice of first- and second-line therapy for a patient with triple-negative breast cancer.
During a Targeted Oncology case-based roundtable event, Thomas Hutson, DO, PharmD, discussed the most recent data supporting immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations for frontline treatment of patients with renal cell carcinoma.
During a live virtual event, Thomas Hutson, DO, PharmD, discussed the outcomes of the CLEAR trial of lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma.
During a Targeted Oncology case-based roundtable event, Alan H. Bryce, MD, discussed the case of a patient with high-volume, hormone-naive metastatic prostate cancer.
During a Targeted Oncology case-based event, Jason Luke, MD, and Laura K. Ferris, MD, PhD, discussed treatment for a patient with basal cell carcinoma.